Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Single Ascending-Dose Study of Selective ErbB4 Agonist JK07 in Heart Failure With Reduced Ejection Fraction.
Journal: JACC. Basic to translational science
Published: March 06, 2025
Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial.
Journal: Lupus science & medicine
Published: January 29, 2025
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus.
Journal: Expert opinion on investigational drugs
Published: May 29, 2024
Absolute and Relative Bioavailability of Oral Solid Dosage Formulations of Deucravacitinib in Humans.
Journal: Clinical pharmacology in drug development
Published: December 07, 2022
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: September 09, 2022
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.
Journal: Annals of the rheumatic diseases
Published: October 12, 2021
Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects.
Journal: Clinical pharmacology in drug development
Published: May 03, 2021
The safety and pharmacokinetics of a novel, selective S1P1R modulator in healthy participants.
Journal: Expert opinion on investigational drugs
Published: April 21, 2020
Population Pharmacokinetic Analysis of BMS-986166, a Novel Selective Sphingosine-1-Phosphate-1 Receptor Modulator, and Exposure-Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants.
Journal: Clinical pharmacology in drug development
Published: September 05, 2018
Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient setting.
Journal: Current medical research and opinion
Published: December 14, 2017
Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarin.
Journal: Hospital practice (1995)
Published: July 28, 2015
Showing 1-11 of 11
Last Updated: 09/26/2026